Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.14 Million EUR | -88.95% |
| 2022 | -8.72 Million EUR | 12.6% |
| 2021 | -9.98 Million EUR | 65.17% |
| 2020 | -28.66 Million EUR | -42.18% |
| 2019 | -20.16 Million EUR | 11.1% |
| 2018 | -22.67 Million EUR | -32.72% |
| 2017 | -17.08 Million EUR | 9.41% |
| 2016 | -18.86 Million EUR | -33.35% |
| 2015 | -14.14 Million EUR | -245.53% |
| 2014 | -4.09 Million EUR | 50.62% |
| 2013 | -8.29 Million EUR | 22.33% |
| 2012 | -10.67 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.09 Million EUR | 0.0% |
| 2023 Q4 | -4.38 Million EUR | 0.0% |
| 2023 Q3 | -4.38 Million EUR | -6.61% |
| 2023 FY | -16.48 Million EUR | -88.95% |
| 2023 Q1 | -3.68 Million EUR | -149.42% |
| 2023 Q2 | -4.11 Million EUR | -11.65% |
| 2022 Q2 | -1.73 Million EUR | -123.64% |
| 2022 Q3 | -1.47 Million EUR | 14.71% |
| 2022 Q4 | -1.47 Million EUR | 0.0% |
| 2022 FY | -8.72 Million EUR | 12.6% |
| 2022 Q1 | 7.33 Million EUR | 252.06% |
| 2021 FY | -9.98 Million EUR | 65.17% |
| 2021 Q3 | -1.39 Million EUR | 75.4% |
| 2021 Q4 | -4.82 Million EUR | -244.48% |
| 2021 Q1 | -2.75 Million EUR | 81.14% |
| 2021 Q2 | -5.69 Million EUR | -106.2% |
| 2020 Q2 | -12.56 Million EUR | -100.03% |
| 2020 Q1 | -6.28 Million EUR | -41.6% |
| 2020 Q4 | -14.63 Million EUR | -100.0% |
| 2020 Q3 | -7.31 Million EUR | 41.77% |
| 2020 FY | -28.66 Million EUR | -42.18% |
| 2019 Q1 | -5.6 Million EUR | 36.22% |
| 2019 Q4 | -4.43 Million EUR | 25.82% |
| 2019 Q2 | -4.13 Million EUR | 26.14% |
| 2019 FY | -20.16 Million EUR | 11.1% |
| 2019 Q3 | -5.98 Million EUR | -44.44% |
| 2018 Q2 | -4.05 Million EUR | 3.2% |
| 2018 Q3 | -5.48 Million EUR | -35.37% |
| 2018 FY | -22.67 Million EUR | -32.72% |
| 2018 Q4 | -8.78 Million EUR | -60.25% |
| 2018 Q1 | -4.18 Million EUR | 29.46% |
| 2017 FY | -17.08 Million EUR | 9.41% |
| 2017 Q4 | -5.93 Million EUR | -65.5% |
| 2017 Q3 | -3.58 Million EUR | 14.15% |
| 2017 Q2 | -4.17 Million EUR | -27.43% |
| 2017 Q1 | -3.27 Million EUR | 6.88% |
| 2016 Q2 | -3.28 Million EUR | 5.64% |
| 2016 Q3 | -5.31 Million EUR | -61.79% |
| 2016 Q1 | -3.47 Million EUR | -9.37% |
| 2016 FY | -18.86 Million EUR | -33.35% |
| 2016 Q4 | -3.51 Million EUR | 33.73% |
| 2015 Q2 | -2.44 Million EUR | -8.25% |
| 2015 FY | -14.14 Million EUR | -245.53% |
| 2015 Q4 | -3.18 Million EUR | -23.5% |
| 2015 Q3 | -2.57 Million EUR | -5.53% |
| 2015 Q1 | -2.25 Million EUR | -330.94% |
| 2014 Q3 | -1.84 Million EUR | -391.22% |
| 2014 Q4 | 976 Thousand EUR | 152.84% |
| 2014 Q2 | -376 Thousand EUR | 86.79% |
| 2014 Q1 | -2.84 Million EUR | -76.28% |
| 2014 FY | -4.09 Million EUR | 50.62% |
| 2013 Q4 | -1.61 Million EUR | 19.21% |
| 2013 Q3 | -1.99 Million EUR | 8.34% |
| 2013 Q2 | -2.18 Million EUR | 12.34% |
| 2013 FY | -8.29 Million EUR | 22.33% |
| 2013 Q1 | -2.48 Million EUR | 26.19% |
| 2012 Q3 | -2.3 Million EUR | 0.0% |
| 2012 FY | -10.67 Million EUR | 0.0% |
| 2012 Q4 | -3.37 Million EUR | -46.37% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -409.71% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1633.879% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -514.61% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 9.514% |
| GB Sciences, Inc. | -1.42 Million USD | -1036.846% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -374.276% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -7237.853% |
| Skye Bioscience, Inc. | -13.67 Million USD | -18.119% |
| Zenith Capital Corp. | -8.94 Million USD | -80.577% |
| Agentix Corp. | -1.37 Million USD | -1077.25% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -220.132% |
| Biomind Labs Inc. | -1 Million USD | -1499.54% |
| ContraFect Corporation | -56.88 Million USD | 71.613% |
| CSL Limited | 3.7 Billion USD | 100.436% |
| CytoDyn Inc. | -18.05 Million USD | 10.571% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -766.191% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -4045.34% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 70.907% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3786.839% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -951.334% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2250.826% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 119.73% |
| SQZ Biotechnologies Company | -75.82 Million USD | 78.702% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -712.946% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 77.504% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -466.531% |
| Mesoblast Limited | -84.14 Million USD | 80.809% |
| Marizyme, Inc. | -34.08 Million USD | 52.623% |
| Genus plc | 6.4 Million USD | 352.328% |
| Pharming Group N.V. | -4.87 Million USD | -230.953% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -93.401% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1051.862% |
| IMV Inc. | -38.67 Million USD | 58.241% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -487.057% |
| MultiCell Technologies, Inc. | -722.81 USD | -2234097.092% |
| ONE Bio Corp. | 13.68 Million USD | 218.035% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 72.624% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 556.186% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -456.622% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -142.915% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -53816.266% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1.76% |
| Alpha Cognition Inc. | -9.7 Million USD | -66.388% |
| Enzolytics Inc. | -2.14 Million USD | -651.536% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 96.201% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1446.839% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -453.153% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.116% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 428.578% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -6070.193% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -557.715% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -9315.803% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -705.534% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 265.759% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -254.555% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -331.052% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1541.07% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3243.049% |
| Q BioMed Inc. | -3.44 Million USD | -368.683% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1185.748% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 70.623% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -107.598% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -735.606% |
| HST Global, Inc. | -140.9 Thousand USD | -11360.751% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1109.273% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1335.587% |
| Halberd Corporation | -75.05 Thousand USD | -21417.655% |
| Resverlogix Corp. | -12.74 Million USD | -26.669% |
| Cell Source, Inc. | -4.32 Million USD | -273.357% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -922.506% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 341.286% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -92598.467% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -554.664% |
| Kadimastem Ltd | -3.04 Million USD | -431.173% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -281.015% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -8798.256% |
| LadRx Corporation | -3.82 Million USD | -322.348% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2250.826% |
| Affymax, Inc. | -15.04 Million USD | -7.331% |
| Itoco Inc. | -919.14 Thousand USD | -1656.968% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1343.164% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2812.091% |
| International Stem Cell Corporation | -663 Thousand USD | -2335.747% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -322.732% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -64059.714% |
| Qrons Inc. | -643.67 Thousand USD | -2408.867% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2759.632% |
| SYBLEU INC | -149.18 Thousand USD | -10725.178% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -624.21% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2332.078% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -789.105% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -30578.191% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -79295.28% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 55.471% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -898.084% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2094.65% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -419.094% |
| Neutra Corp. | -229.48 Thousand USD | -6937.031% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 7.925% |
| PureTech Health plc | -146.19 Million USD | 88.954% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 24.857% |
| IXICO plc | -1.43 Million USD | -1023.8% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -70.151% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 86.742% |
| CSL Limited | 3.81 Billion USD | 100.424% |
| Cellectis S.A. | -108.85 Million USD | 85.165% |